Aeterna Zentaris (AEZS) Posts Q3 Loss of 19c, Beats by 2c
More News related to AEZS
- AEterna Zentaris (AEZS) Reports That Perifosine Partner Keryx Biopharma (KERX) Will Prersent Data from Phase 1/2 at 51st ASH Meeting
- AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine (KRX-0401) at 51st Annual Meeting of the American Society of Hematology
- Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
- Aeterna Zentaris (AEZS) Posts Q3 Loss of 19c, Beats by 2c
- AEterna Zentaris Reports Third Quarter 2009 Financial and Operating Results
Aeterna Zentaris Inc. (NASDAQ: AEZS) reports Q3 loss of $0.19, 2 cents better than the analyst estimate of ($0.21). Revenue for the quarter was $8.57 million, which compares to the estimate of $8.04 million.
Related Categories
EarningsStocks Mentioned
+0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
